News
Latest news from CHV and our portfolio companies
Featured News
Milestone marks the commercial use of the first and only liquid embolic approved for hypervascular tumor embolization supported by a prospective, randomized, controlled clinical trial BEDFORD, Mass., January 28th, 2026 – Instylla,…
Insights & Impacts: The latest from CHV
PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage company redefining cancer treatment with therapeutics administered
EyeCool Therapeutics, Inc., a clinical-stage medical device company pioneering a novel approach for the treatment
AtaCor Medical, Inc., a privately-held medical device company focused on transforming cardiac rhythm management, announced
Esperto Medical™, Inc. a healthtech startup specializing in critical care and remote patient monitoring, announces
Sera Prognostics, Inc., The Pregnancy Company® (“Sera” or the “Company”) (Nasdaq: SERA), which focuses on
Epitel, Inc., a leader in AI technologies for patient-focused brain health solutions, is pleased to
Rejoni, Inc., a privately held clinical-stage company, today announced the completion of enrollment of 150
Sera Prognostics, Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health
Study will assess the Company’s Next-Generation device under Intracardiac Echocardiography (ICE) imaging for Left Atrial
Funding Will Support Clinical Studies of the VelocityTM pAVF System in Patients with Chronic Kidney